Endocrine resistance in breast cancer

Climacteric

Volumn 17, Issue 5, 2014, Pages 522-528

  Zheng, L H ^a   Zhao, Y H ^a   Feng, H L ^a   Liu, Y J ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

breast cancer; endocrine resistant; estrogens

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; ADAPTOR PROTEIN; CCN PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBRONECTIN; GLUTAMIC ACID; HISTONE DEMETHYLASE; HISTONE SPECIFIC DEMETHYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 451; NOTCH RECEPTOR; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PROLINE DERIVATIVE; PROLINE GLUTAMIC ACID AND LEUCINE RICH PROTEIN 1; PROTEIN KINASE B; PROTEIN KINASE FER; SCLEROPROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; STEROID RECEPTOR COACTIVATOR 1; SYNAPSIN I; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL PROLIFERATION; GENE OVEREXPRESSION; HORMONE RESISTANCE; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENETICS; MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; HUMANS; MICE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84907873145     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.864268     Document Type: Article

References (42)

1. Gruber C J, Tschugguel W, Schneeberger C, Huber J C. Production and actions of estrogens. N Engl J Med 2002; 346: 340-52
2. Lin CY, Ström A, Vega VB, et al. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol 2004; 5: R66
3. Lawson JS, Field AS, Tran DD, et al. Breast cancer incidence and estrogen receptor alpha in normal mammary tissue-An epidemiologic study among Japanese women in Japan and Hawaii. Int J Cancer 2002; 97: 685-7
4. B oswell K A, Wang X, Shah M V, Aapro M S. Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER-) advanced breast cancer: A review of the literature. Breast 2012; 21: 701-6
5. Ma CX, S anchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology 2009; 23: 133-42
6. Osborne C K, Fuqua S A. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994; 32: 49-55
7. Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3f and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012; 31: 39-47
8. Tomlinson DC, Knowles MA, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 2012; 130: 2857-66
9. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004; 279: 51323-30
10. Roy R, Moses M A. ADAM12 induces estrogen-independence in breast cancer cells. Breast Cancer Res Treat 2012; 131: 731-41
11. Pontiggia O, Sampayo R, Raffo D, et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: A role for soluble stromal factors and fibronectin through b1 integrin. Breast Cancer Res Treat 2012; 133: 459-71
12. Cortez V, Mann M, Tekmal S, et al. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 2012; 14: R108
13. Pietras R J, Arboleda J, Reese D M, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-46
14. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-Talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-35
15. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001; 8: 191-5
16. Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifeninduced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 1996; 2: 1215-19
17. Nicholson R I, McClelland R A, Finlay P, et al. Relationship between EGF-R, c-erb B-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29A: 1018-23
18. Magnani L, Stoeck A, Zhang X, et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci USA 2013; 110: E1490-9
19. Guo S, Li Y, Tong Q, et al. ?EF1 down-regulates ER-?expression and confers tamoxifen resistance in breast cancer. PLoS ONE 2012; 7: E52380
20. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45
21. Sabatini DM. mTOR and cancer: Insights into a complex relationship . Nat Rev Cancer 2006; 6: 729-34
22. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4: 335-48
23. Carraway H, Hidalgo M. New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004; 6: 219-24
24. Sokolosky ML, Stadelman KM, Chappell WH, et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011; 2: 538-50
25. Alers S, Löffl er AS, Wesselborg S, Stork B. Role of AMPKmTOR-Ulk1/2 in the regulation of autophagy: Cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012; 32: 2-11
26. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: A central node of complex signaling cascades. Int J Clin Exp Pathol 2011; 4: 476-95
27. Cavazzoni A, Bonelli M A, Fumarola C, et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/ mTOR pathway in breast cancer cell clones. Cancer Letters 2012; 323: 77-87
28. Ramaswamy B, Lu Y, Teng K Y, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 2012; 72: 5048-59
29. Vilquin P, Villedieu M, Grisard E, et al. Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer 2013; 133: 1589-602
30. Stebbing J, Filipovic A, Lit LC, et al. LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene 2012; 32: 3371-80
31. Wong C, Wang X, Smith D, Reddy K, Chen S. AKT-Aro and HER2-Aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Breast Cancer Res Treat 2012; 134: 671-81
32. Molloy CA, May FE, Westley BR. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 2000; 275: 12565-71
33. Becker M A, Ibrahim Y H, Cui X, Lee A V, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 2011; 25: 516-28
34. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: Implications for breast cancer treatment. Cancer Res 2012; 72: 3372-80
35. Caldon CE, Sergio CM, Kang J, et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 2012; 11: 1488-99
36. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008; 26: 535-84
37. A guilar H, Sol é X, Bonifaci N, et al. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010; 29: 6071-83
38. Cutrupi S, Reineri S, Panetto A, et al. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene 2012; 31: 4353-61
39. McBryan J, Theissen SM, Byrne C, et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res 2012; 72: 548-59
40. Qin L, Liu Z, Chen H, Xu J. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res 2009; 69: 3819-27
41. Goel A, Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 2004; 279: 14909-16
42. McCartan D, Bolger JC, Fagan A, et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res 2012; 72: 220-9